Please ensure Javascript is enabled for purposes of website accessibility

FDA Denies Approval for Gilead Sciences' Potential Blockbuster Arthritis Drug

By Cory Renauer – Aug 19, 2020 at 11:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Onlookers had been expecting a thumbs up for filgotinib. Now, that won't happen for at least another year.

The space for oral rheumatoid arthritis treatments won't be getting crowded quite as quickly as some might have been expecting. Gilead Sciences (GILD -1.02%) told investors on Tuesday that the FDA has issued a complete response letter (CRL) denying approval for its drug candidate filgotinib -- for now -- and dealing a huge blow to the company's cash flow projections.

An FDA approval for filgotinib had been widely expected, and forecasts of its market potential suggested it would likely become a blockbuster. Sales had been expected to exceed $1 billion in 2022 and peak above $4 billion annually.

This setback for Gilead's drug will give recently launched oral rheumatoid arthritis (RA) treatments from AbbVie (ABBV -1.09%) and Eli Lily (LLY -1.89%) more time to establish their footholds in the highly lucrative market for immune system suppressants that safely prevent the disease from progressing. 

A very upset doctor.

Image source: Getty Images.

AbbVie's injectable RA treatment, Humira is the world's top-selling drug; its annual sales peaked at $19.9 billion in 2018. In 2019, AbbVie launched Rinvoq, an oral RA treatment similar to filgotinib that generated an annualized $596 million during the second quarter. 

Rinvoq and a similar RA treatment from Eli Lilly called Olumiant have both been associated with life-threatening blood clots, though that side effect has been extremely uncommon. Because it has exhibited fewer serious side effects during clinical trials, filgotinib was expected to give Rinvoq and Olumiant fierce competition. 

According to Gilead Sciences, the FDA wants to see data from ongoing studies designed to measure whether or not filgotinib impacts sperm counts. An ongoing study to assess testicular safety that began in 2017 isn't expected to produce preliminary results until January 2021, which means it's going to be at least another year before the FDA takes another look at filgotinib.

Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences Stock Quote
Gilead Sciences
$64.29 (-1.02%) $0.66
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$326.66 (-1.89%) $-6.29
AbbVie Inc. Stock Quote
AbbVie Inc.
$138.76 (-1.09%) $-1.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.